Characterizing Myositis With 68Ga-FAPI PET/CT

Last updated: July 12, 2023
Sponsor: The First Affiliated Hospital of Xiamen University
Overall Status: Active - Recruiting

Phase

1

Condition

Idiopathic Inflammatory Myopathies

Myositis

Treatment

68Ga-FAPI

Clinical Study ID

NCT05952531
FAPI in IIM
  • Ages 18-75
  • All Genders

Study Summary

To evaluate the potential usefulness of 68Ga-FAPI PET/CT for the diagnosis and evaluation of systemic involvement in idiopathic inflammatory myopathies (IIM)/myositis, and compared the results with those of 18F-FDG PET/CT.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. A diagnosis of myositis according to American College of Rheumatology/European LeagueAgainst Rheumatism 2017 (ACR/EULAR 2017) criteria
  2. Adult men or women 18 and ≤ 75 years of age at the time of signing the informedconsent (ICF).
  3. Participants who were able to provide informed consent (signed by participant or legalrepresentative) and assent according to the guidelines of the Clinical Research EthicsCommittee.
  4. 68Ga-FAPI and 18F-FDG PET/CT were performed within two weeks.

Exclusion

Exclusion Criteria:

  1. Pregnancy;
  2. Breastfeeding;
  3. known allergy against FAPI;
  4. any medical condition that in the opinion of the investigator may significantlyinterfere with study compliance.

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: 68Ga-FAPI
Phase: 1
Study Start date:
July 01, 2023
Estimated Completion Date:
July 31, 2025

Study Description

Inflammatory myopathies (IIM), collectively known as myositis, are heterogeneous systemic autoimmune disorders characterized by muscle inflammation, and frequently accompanied by extra-muscular manifestations that affect the skin, lung, and joints. Prevalence of underlying malignancy is high in patients with IIM.

68Ga-FAPI has been developed as tracers specific for fibroblast-activation protein (FAP), which is overexpressed in activated fibroblasts in various type of cancers and autoimmune diseases, such as rheumatoid arthritis, IgG4-related diseases and interstitial lung diseases.

Recently the investigators have published articles of the application of 68Ga-FAPI in IgG4-related disease and rheumatoid arthritis, which showed it was more sensitive than FDG in detecting a certain type of inflammation, and the potential utility of FAP-targeted PET/CT imaging for disease assessment in myositis have been reported in a case recently.

Thus, this prospective study is going to investigate utility of 68Ga-FAPI PET/CT in diagnosis, disease assessment including skeletal muscle involvement, cardiac involvement, interstitial lung diseases and potential underlying cancer screening, response to treatment and prognosis, compared with 18F-FDG PET/CT.

Connect with a study center

  • The first affiliated hospital of Xiamen University

    Xiamen, Fujian 361000
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.